SCHEDULE 13G: Goldman Sachs Discloses 7.0% Passive Stake in Syndax Pharmaceuticals
Beneficial Ownership Statement
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have disclosed a passive beneficial ownership of 7.0% in Syndax Pharmaceuticals, Inc. common stock as of December 31, 2024.
Summary
- The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly reported beneficial ownership of 5,953,465.21 shares of Syndax Pharmaceuticals, Inc. common stock.
- This aggregate amount represents 7.0% of the total outstanding common stock of Syndax Pharmaceuticals, Inc.
- The filing is a Schedule 13G, indicating that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- Goldman Sachs & Co. LLC, a subsidiary of The Goldman Sachs Group, Inc., is identified as the entity primarily holding these securities, operating as a registered broker-dealer and investment adviser.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive. While a 13G is a routine disclosure, a significant stake by a prominent institution like Goldman Sachs can be viewed favorably by the market, suggesting confidence in the issuer. However, it provides no operational or financial performance details of the issuer.
Positives
- The disclosure of a significant 7.0% stake by a major institutional investor like Goldman Sachs can be perceived as a positive signal of confidence in Syndax Pharmaceuticals, Inc. by the market.
- The passive nature of the investment, as indicated by the Schedule 13G filing, suggests that Goldman Sachs views the shares as a long-term holding without immediate intentions to influence corporate control.
Risks
- This Schedule 13G filing itself does not detail specific risks related to Syndax Pharmaceuticals, Inc.'s operations, financial health, or strategic outlook. It is solely a disclosure of beneficial ownership.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Syndax Pharmaceuticals, Inc.'s future performance or strategic outlook. It is a disclosure of current beneficial ownership.
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Ameen Soetan, Attorney-in-fact for The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC)
Industry Context
The filing indicates a significant institutional investment in a pharmaceutical company, which is common for large financial institutions like Goldman Sachs. Such investments reflect a belief in the long-term value or growth potential within the biotechnology and pharmaceutical sectors, often driven by pipeline developments, market opportunities, or strategic positioning of the target company.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may instill confidence among existing shareholders and potentially attract new investors, possibly leading to positive share price movement.
- Company Management: While the investment is passive, the presence of a major institutional investor on the shareholder register can influence management's focus on shareholder value and corporate governance.
Next Steps
- Goldman Sachs will continue to hold its passive stake in Syndax Pharmaceuticals, Inc. as disclosed.
- Further Schedule 13G/A amendments would be filed if there are material changes to their beneficial ownership (e.g., crossing a 1% threshold up or down, or changing investment intent).
Key Dates
| Date | Description |
|---|---|
| 2023-12-01 | Previous Power of Attorney granted by Goldman Sachs & Co. LLC superseded. |
| 2024-02-09 | Previous Power of Attorney granted by The Goldman Sachs Group, Inc. superseded. |
| 2024-07-29 | Effective date of new Power of Attorney for The Goldman Sachs Group, Inc. |
| 2024-10-01 | Effective date of new Power of Attorney for Goldman Sachs & Co. LLC. |
| 2024-12-31 | Date of event which requires the filing of this statement (beneficial ownership calculation date). |
| 2025-01-28 | Filing date of the Schedule 13G statement. |
| 2025-07-29 | Expiration date of the Power of Attorney for The Goldman Sachs Group, Inc., unless earlier revoked. |
| 2025-10-01 | Expiration date of the Power of Attorney for Goldman Sachs & Co. LLC, unless earlier revoked. |
Keywords
Beneficial Ownership, SEC Filing, Schedule 13G, Goldman Sachs Group, Goldman Sachs & Co. LLC, Syndax Pharmaceuticals Inc., Common Stock, Institutional Investment, Passive Investment, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.